Reasons Why You Should Hold Insperity Stock in Your Portfolio

Insperity's Q2 2026 adjusted EPS rose 31% year over year to $0.34 and adjusted EBITDA increased 13% to $36 million, aided by pricing, benefits-plan changes and an 8% reduction in operating expenses. Management reaffirmed full-year adjusted EBITDA guidance of $185-$225 million and adjusted EPS guidance of $1.88-$2.43; shares have gained 90.9% over six months. The company ended Q2 with $700 million of cash and marketable securities and no current debt, but benefits costs per covered employee rose 5.2%, creating second-half margin risk.

Analysis

NSP's investable issue is not top-line growth but whether pricing and plan-design actions can permanently reprice its medical-benefit risk. The PEO model effectively embeds a self-insurance-style underwriting exposure alongside payroll administration; a modest miss in medical trend or workers' compensation severity can consume the operating leverage implied by cost cuts. After a near-doubling in six months, the market is likely discounting the upper half of management's earnings range, leaving little tolerance for a benefits-cost reserve build in the next two quarterly reports.

The second-order read-through is mixed for PEO peers. ADP and PAYX have more diversified payroll/software economics and less acute benefit-cost pass-through sensitivity, while NSP's improvement would validate pricing power among smaller employers that have been reluctant to absorb HR-service price increases. PAYC is not a direct PEO comparable: its upside depends more on payroll-suite adoption and sales execution than medical-cost normalization, so the article's favorable association is not a fundamental catalyst for PAYC.

Contrarian view: the cash balance and shareholder returns should not be valued as fully excess capital until benefit-cost volatility is resolved; PEO client funds and regulatory/working-capital needs make headline liquidity less informative than operating cash conversion. Near term, the stock can remain momentum-supported, but the 1-3 month catalyst is benefits-cost commentary and retention versus price realization, not another generic margin-recovery narrative. A 6-18 month rerating requires evidence that margins recover without sacrificing worksite-employee growth or client retention.

The key falsifier for a cautious stance is two consecutive quarters of benefit costs at or below management's planning assumptions, stable retention, and EBITDA tracking toward the upper half of guidance. Conversely, any reduction in full-year EBITDA guidance, acceleration in per-employee healthcare trend, or reserve-related cash-flow deterioration should trigger estimate cuts and multiple compression.

Key Decisions for Investors

• Do not chase NSP after the sharp run; maintain a watchlist rather than initiate outright exposure until the next earnings release establishes benefits-cost trend and client retention. Upgrade to a long only if EBITDA guidance is maintained or raised and benefit-cost commentary narrows rather than widens the outcome range.
• For a 1-3 month relative-value expression, consider long ADP or PAYX versus short NSP in equal beta-adjusted dollars if NSP trades into earnings without a guidance increase. The thesis is that diversified payroll platforms retain recurring-revenue defensiveness while NSP bears asymmetric insurance-cost and reserve risk; cover the short if NSP raises its EBITDA outlook or reports materially better medical-cost trend.
• If existing long NSP exposure must be retained, buy a post-earnings downside hedge using 3-6 month put spreads rather than adding equity. Size the hedge around a 15-20% downside scenario, reflecting the risk that the market resets from an upper-range to a midpoint-or-lower-range earnings outcome.
• Treat PAYC separately: monitor bookings, sales productivity, and retention for its next catalyst rather than using NSP's margin recovery as a read-through. There is no actionable fundamental linkage in the supplied information.